Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study
Open Access
- 4 September 2024
- journal article
- Published by Elsevier in EBioMedicine
- Vol. 108, 105320
Abstract
No abstract availableKeywords
Funding Information
- Icahn School of Medicine at Mount Sinai
- Massachusetts Institute of Technology
- Bill and Melinda Gates Foundation (BMGF/OPP1165951)
- US Army Medical Research and Materiel Command
- Harvard University
- National Institutes of Health
- Massachusetts General Hospital
- HIV Vaccine Trials Network
- Ragon Institute
- Center for AIDS Research, Duke University
- U.S. Public Health Service
- National Institute of Allergy and Infectious Diseases
This publication has 29 references indexed in Scilit:
- Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trialThe Lancet Infectious Diseases, 2024
- Antibody class-switching as a strategy to improve HIV-1 neutralizationTrends in Molecular Medicine, 2022
- Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a studyThe Lancet HIV, 2020
- Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody ResponsesCell Reports, 2019
- Maximum diversity weighting for biomarkers with application in HIV‐1 vaccine studiesStatistics in Medicine, 2019
- Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)The Lancet, 2018
- Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus MonkeysCell, 2013
- Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144The Lancet Infectious Diseases, 2012
- Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeysNature Medicine, 2010
- Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variantsNature Medicine, 2006